Read our latest blog, where Dr Mark Eccleston, InaphaeaBioLabs Director and CEO of our parent company ValirxPlcOfficial , discusses CytoLytix – a joint venture between ValirxPlcOfficial and King's College London that focuses on developing treatments for triple-negative breast cancer:

We've just posted the following update on our investor hub: New Evaluation and Option Agreement. Check out the full update and join in with the conversation at: valirx.com/activity-updat… #val

We've just posted the following update on our investor hub: Extension of Evaluation Agreement Dundee University. Check out the full update and join in with the conversation at: valirx.com/activity-updat… #ValiRxDundeeUniProject #DrugDiscovery #ConnectedInnovation

We've just released the following announcement: ValiRx PLC - Inaphaea Evaluation and Commercial Use Agreement Check out the full announcement and join in with the conversation at: valirx.com/announcements/… #ValiRxConnectedInnovation #PDCs #DrugDiscovery #Assays #AssayDevelopment

We've just posted the following update on our investor hub: World Cancer Day Check out the full update and join in with the conversation at: valirx.com/activity-updat… #WorldCancerDay #CancerResearch #AssayDevelopment

We've just posted the following update on our investor hub: Celebrating International Day of Women and Girls in Science. Check out the full update and join in with the conversation at: valirx.com/activity-updat… #WomenInScience #WomenInSTEM #IDWGS #STEMCareers

We've just posted the following update on our investor hub: Cancer Prevention Week Check out the full update and join in with the conversation at: valirx.com/activity-updat… #CancerResearch #CancerPrevention #CPAW25 #PatientDerivedCells #AssayDevelopment #DrugDiscovery

In this interview, Mark Eccleston, CEO of ValiRx, outlines the company’s strategic approach to selecting and managing early-stage assets. Watch at the link below, and submit your questions for the management team! valirx.com/activity-updat… #val

We've just posted the following update on our investor hub: Driving Growth: ValiRx and Inaphaea announce new appointments Check out the full update and join in with the conversation at: valirx.com/activity-updat… #ValiRxDrivingGrowth #DrugDiscovery #ResearchandDevelopment

Our Director of Research, Michelle Barnard is attending the Women's Health Endometriosis Event at UoD Life Sciences to discuss approaches to drug discovery and development of Endometriosis therapeutics including ValiRx’s VAL301. Find out more about VAL301: bit.ly/426Fu67

We've just posted the following update on our investor hub: ValiRx CEO features in the Inspirational Leaders Magazine Check out the update and join in the conversation at: valirx.com/activity-updat… #AssayDevelopment #BioTech #DrugDiscovery #CancerResearch #ScientificResearch

ValiRx CEO Dr Mark Eccleston featured in The Inspirational Leaders magazine. Mark's commitment to accelerating early-stage drug development is a testament to the leadership needed to bring drug candidates to the clinic. The Inspirational Leaders Read more: bit.ly/4hKooR9

ValiRx CEO Mark Eccleston and Director of Research Michelle Barnard are attending the 4th Ace Drug Discovery Summit in London next week. Be sure to catch Mark’s talk on 2 April at 4pm. #4thADDSLondon #DrugDiscovery #CancerResearch #ScientificResearch #Event #Networking

We recently released an RNS on the Termination of Letter of Intent with TheoremRx. Hear from CEO, Dr Mark Eccleston, as he discusses why we chose this course, and what comes next at ValiRx. Please feel free to submit your questions via our website. valirx.com/announcements/… #val

Mark Eccleston, CEO, discusses Pro-Senescence cancer therapeutics. He explores the science behind the approach, as well as partnerships, funding, and repurposing existing drugs via evaluation agreements. Watch below! valirx.com/activity-updat… #CancerResearch #DrugDiscovery #val

ValiRx CEO, Dr Mark Eccleston is attending the 2025 ASCO Annual Meeting, later this week. Mark will be available to speak to fellow delegates about our drug pipeline and development services. To book a meeting with Mark, get in touch: bit.ly/3H8JKef #ASCO2025

ValiRx's Mark Eccleston shares how an unconventional operating model, focused evaluation program & a scalable SPV strategy are shaping the company’s next phase. He also discusses major opportunities in immuno-oncology and the tCRO model. Watch here: valirx.com/activity-updat… #val

We are pleased to announce that our subsidiary, Cytolytix Ltd and Omios Biologics, a California-based corporation, have entered into an Evaluation and Material Transfer agreement. Find out more about the agreement here: bit.ly/43rz9Ux #CancerResearch #AssayDevelopment

ValiRx Investor Webinar - hear from the team this Thursday June 12, at 10am BST. Follow the link below to sign up and submit your questions in advance: valirx.com/webinars/XyO1X… #val #ValiRx #BioTech #ImmunoOncology #TranslationalResearch #BusinessModels #LifeSciences #Innovation

ValiRx CEO Dr Mark Eccleston is attending the life sciences flagship partnering event next week: The BIO International Convention. If you’d like to book a meeting with Mark, please do so via BIO’s official partnering platform: bit.ly/4kzEUWn Biotechnology Innovation Organization #BIO2025